659 related articles for article (PubMed ID: 32121289)
1. METTL3 Modulates Osteoclast Differentiation and Function by Controlling RNA Stability and Nuclear Export.
Li D; Cai L; Meng R; Feng Z; Xu Q
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121289
[TBL] [Abstract][Full Text] [Related]
2. METTL3 Regulates Osteoblast Differentiation and Inflammatory Response via Smad Signaling and MAPK Signaling.
Zhang Y; Gu X; Li D; Cai L; Xu Q
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31892163
[TBL] [Abstract][Full Text] [Related]
3. YTHDF1 regulates endoplasmic reticulum stress, NF-κB, MAPK and PI3K-AKT signaling pathways in inflammatory osteoclastogenesis.
He M; Li D; Fang C; Xu Q
Arch Biochem Biophys; 2022 Dec; 732():109464. PubMed ID: 36368367
[TBL] [Abstract][Full Text] [Related]
4. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
5. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
6. YTHDF2 mediates LPS-induced osteoclastogenesis and inflammatory response via the NF-κB and MAPK signaling pathways.
Fang C; He M; Li D; Xu Q
Cell Signal; 2021 Sep; 85():110060. PubMed ID: 34089814
[TBL] [Abstract][Full Text] [Related]
7. METTL3 Regulates Osteoclast Biological Behaviors via iNOS/NO-Mediated Mitochondrial Dysfunction in Inflammatory Conditions.
Li D; He J; Fang C; Zhang Y; He M; Zhang Z; Hou J; Xu Q
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674918
[TBL] [Abstract][Full Text] [Related]
8. YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m
Chai RC; Chang YZ; Chang X; Pang B; An SY; Zhang KN; Chang YH; Jiang T; Wang YZ
J Hematol Oncol; 2021 Jul; 14(1):109. PubMed ID: 34246306
[TBL] [Abstract][Full Text] [Related]
9. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
10. Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.
Lin X; Xiao Y; Chen Z; Ma J; Qiu W; Zhang K; Xu F; Dang K; Qian A
Mol Cell Endocrinol; 2019 Aug; 494():110494. PubMed ID: 31260729
[TBL] [Abstract][Full Text] [Related]
11. Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation.
Kong X; Wu W; Yang Y; Wan H; Li X; Zhong M; Zhao H; Su X; Jia S; Ju D; Lin N
J Transl Med; 2015 Mar; 13():91. PubMed ID: 25889035
[TBL] [Abstract][Full Text] [Related]
12. Cinchonine inhibits osteoclast differentiation by regulating TAK1 and AKT, and promotes osteogenesis.
Jo YJ; Lee HI; Kim N; Hwang D; Lee J; Lee GR; Hong SE; Lee H; Kwon M; Kim NY; Kim HJ; Park JH; Kang YH; Kim HS; Lee SY; Jeong W
J Cell Physiol; 2021 Mar; 236(3):1854-1865. PubMed ID: 32700766
[TBL] [Abstract][Full Text] [Related]
13. Corilagin suppresses RANKL-induced osteoclastogenesis and inhibits oestrogen deficiency-induced bone loss via the NF-κB and PI3K/AKT signalling pathways.
Lu J; Ye C; Huang Y; Huang D; Tang L; Hou W; Kuang Z; Chen Y; Xiao S; Yishake M; He R
J Cell Mol Med; 2020 Sep; 24(18):10444-10457. PubMed ID: 32681612
[TBL] [Abstract][Full Text] [Related]
14. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.
Han SY; Lee KH; Kim YK
Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250
[TBL] [Abstract][Full Text] [Related]
15. The RNA-binding protein Cpeb4 is a novel positive regulator of osteoclast differentiation.
Arasaki Y; Li M; Akiya T; Nozawa I; Ezura Y; Hayata T
Biochem Biophys Res Commun; 2020 Aug; 528(4):621-627. PubMed ID: 32517870
[TBL] [Abstract][Full Text] [Related]
16. Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling.
Hu B; Sun X; Yang Y; Ying Z; Meng J; Zhou C; Jiang G; Li S; Wu F; Zhao X; Zhu H; Wu H; Cai X; Shi Z; Yan S
FASEB J; 2019 Feb; 33(2):2574-2586. PubMed ID: 30285579
[TBL] [Abstract][Full Text] [Related]
17. Annexin A3 accelerates osteoclast differentiation by promoting the level of RANK and TRAF6.
Lin S; Li M; Zhou Y; Chen L; Wang Y; Zhuang Z; Zhao H; Yang R
Bone; 2023 Jul; 172():116758. PubMed ID: 37030499
[TBL] [Abstract][Full Text] [Related]
18. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
Sun X; Zhang J; Wang Z; Liu B; Zhu S; Zhu L; Peng B
Theranostics; 2019; 9(18):5183-5199. PubMed ID: 31410209
[TBL] [Abstract][Full Text] [Related]
19. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
20. Diaporisoindole E inhibits RANKL-induced osteoclastogenesis via suppression of PI3K/AKT and MAPK signal pathways.
Hua P; Cui H; Xu J; Cai R; She Z; Gu Q
Phytomedicine; 2020 Aug; 75():153234. PubMed ID: 32510335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
